无锡烨隆精密机械股份有限公司（以下简称"烨隆股份"）的首次公开募股（IPO）之旅近日画上了句号，但其上市之路却充满了曲折。 烨隆股份早在2023年3月便已递交了招股书，同年9月成功通过IPO审核。然而，令人意外的是，在此后的近两年里，其上市进程却陷入了停滞。直到2025 年5月8日，烨隆股份的IPO最终被终止。 吴云娇和吴云烨均为1980年代末至1990年代初出生，拥有美国永久居留权，且均具备本科学历。两人自2010年代起便在烨隆股份或其前身担任要职，积累 了丰富的行业经验。 尽管烨隆股份在业务发展和财务表现上取得了一定的成绩，但其IPO的终止无疑给公司的未来发展带来了不确定性。对于这一结果，市场各方也给出了不 同的解读和分析。 从财务表现来看，烨隆股份在过去几年的业绩相对稳定。招股书显示，其2020年至2022年的营业收入分别为10.82亿元、11.77亿元和11亿元；净利润分别 为1亿元、1.08亿元和1.03亿元。然而，值得注意的是，公司的存货账面价值也在逐年攀升，从2020年的2.2亿元增长至2022年的3.54亿元，占当期期末流动 资产的比例也相对较高。 | 项目 | 2022.12.31/ | 2 ...

Group 1 - The core point of the article highlights that there are no new IPO applications this week, while the third IPO of the year has been accepted on the Sci-Tech Innovation Board [1][2][4] - Ningbo Jianxin Superconducting Technology Co., Ltd. (referred to as "Jianxin Superconducting") has had its IPO application accepted, aiming to raise 865 million yuan [2][3] - Jianxin Superconducting specializes in the research, production, and sales of core components for medical magnetic resonance imaging (MRI) equipment, with its products accounting for approximately 50% of the cost of MRI equipment [3][4] Group 2 - Jianxin Superconducting is one of the earliest manufacturers in China to produce high-field superconducting magnets at scale, breaking the long-standing monopoly of foreign companies [3] - The company has established partnerships with well-known MRI equipment manufacturers, including Fujifilm, GE Healthcare, and others [3] - In terms of market share, Jianxin Superconducting ranks fifth globally and second domestically in the superconducting magnet sector, with a 4.2% global market share [3] Group 3 - The company plans to use the funds raised from the IPO for projects including the annual production of 600 sets of helium-free superconducting magnets and technological upgrades for high-field medical superconducting magnets [4] - The article notes that Jianxin Superconducting's acceptance for IPO reflects the ongoing effects of the "Eight Articles of the Sci-Tech Innovation Board" policy [4] - In total, 13 IPOs have been accepted this year across the Shanghai, Shenzhen, and Beijing exchanges, with three on the Shanghai exchange, all from the Sci-Tech Innovation Board [4]

Group 1 - The core viewpoint of the news is the acceptance of the IPO application of Ningbo Jianxin Superconducting Technology Co., Ltd. on the Sci-Tech Innovation Board, marking it as the third company to be accepted for IPO this year [1][2]. - Jianxin Superconducting focuses on the research, production, and sales of core components for medical magnetic resonance imaging (MRI) equipment, with its main products including superconducting magnets, permanent magnets, and gradient coils, which account for approximately 50% of the cost of MRI equipment [2][3]. - The company has established partnerships with well-known MRI equipment manufacturers such as Fujifilm, GE Healthcare, and others, positioning itself as a leading independent supplier of superconducting magnets globally [2][3]. Group 2 - Jianxin Superconducting's projected revenues for 2022 to 2024 are 359 million yuan, 451 million yuan, and 425 million yuan, respectively, with net profits of 34.63 million yuan, 48.73 million yuan, and 55.78 million yuan [3]. - The IPO aims to raise 865 million yuan for projects including the annual production of 600 sets of helium-free superconducting magnets and the technological transformation of high-field medical superconducting magnets [3]. - The acceptance of Jianxin Superconducting's IPO application highlights the ongoing effects of the "Eight Policies of the Sci-Tech Innovation Board," with a total of 13 IPOs accepted this year across various exchanges [3][8].

Core Viewpoint - Wuxi Yelong Precision Machinery Co., Ltd. has withdrawn its IPO application, leading to the termination of its review for listing on the Shanghai Stock Exchange [1][3]. Company Overview - Yelong was established in September 2002 and is located in Wuxi, Jiangsu Province, with a registered capital of 210 million yuan [3]. - The actual controllers of Yelong are Wu Yunjiao and Wu Yuyue, who together hold 98.90% of the company's shares [5]. Financial Performance - Yelong's revenue for 2020, 2021, and 2022 was approximately 1.08 billion yuan, 1.18 billion yuan, and 1.10 billion yuan, respectively, with net profits of about 103 million yuan, 108 million yuan, and 103 million yuan [5]. - The company's total assets as of December 31, 2022, were approximately 1.31 billion yuan, with a debt-to-asset ratio of 54.35% [6]. Product and Market Focus - Yelong primarily engages in the R&D, production, and sales of key components for automotive turbochargers, with its main products being turbine housings and precision components [5][7]. - The company has a high customer concentration, with sales to its top five customers accounting for 92.86%, 95.59%, and 98.82% of its revenue in the respective years [7]. Investment Plans - The company planned to raise approximately 571 million yuan through its IPO to fund projects including the technological transformation of its high-performance alloy materials factory and the construction of a research and design center [3].

IPO Review and Registration Progress - Ningbo Jianxin Superconducting Technology Co., Ltd. has received acceptance for its IPO application on the Sci-Tech Innovation Board, marking the third new acceptance this year [2] - The company reported revenues of 359 million yuan, 451 million yuan, and 425 million yuan for 2022 to 2024, with net profits of 34.63 million yuan, 48.73 million yuan, and 55.78 million yuan respectively [2] - The company plans to raise 865 million yuan through its IPO for projects including the production of superconducting magnets and working capital [3] - Lianchuan Biotechnology has also received acceptance for its IPO on the Beijing Stock Exchange, aiming to raise 300 million yuan for projects related to gene technology and working capital [4] - The company reported revenues of 234 million yuan, 287 million yuan, and 367 million yuan from 2022 to 2024, with net profits of 52.76 million yuan, 53.49 million yuan, and 60.06 million yuan respectively [4] - Dana Biotechnology submitted its IPO registration on the Beijing Stock Exchange, focusing on early rapid diagnostic technology for invasive fungal diseases [6] - Han Gao Group's IPO registration has been approved, with projected revenues of 2.857 billion yuan and net profits of 531 million yuan for 2024 [6] New Stock Subscription and Listing Dynamics - Three new stocks are scheduled for subscription this week, including Hanbang Technology, Weigao Blood Purification, and Taili Technology [8] - Hanbang Technology aims to raise 598 million yuan for the production of liquid chromatography equipment, with projected revenues of 691 million yuan and net profits of 79 million yuan for 2024 [8] - Weigao Blood Purification plans to raise 1.351 billion yuan for smart production and other projects, with sales expenses exceeding 600 million yuan from 2022 to 2024 [9] - Taili Technology focuses on new materials and plans to raise 542 million yuan for production and logistics center construction, with projected revenues of 1.02 billion yuan and net profits of 88 million yuan for 2024 [9] Upcoming Listings - Tian Gong Co., Ltd. is set to be listed on the Beijing Stock Exchange on May 13, with projected revenues of 383 million yuan, 1.035 billion yuan, and 801 million yuan from 2022 to 2024 [11] - The company plans to raise 360 million yuan for the construction of high-end titanium and titanium alloy production lines [11] Policy and Regulatory Trends - The China Securities Regulatory Commission (CSRC) plans to introduce policies to deepen reforms in the Sci-Tech Innovation Board and the Growth Enterprise Market, enhancing the system's inclusiveness and adaptability [12]